Gerstle Medicine

Gerstle Medicine is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule drugs. The company's primary focus is on addressing unmet medical needs in autoimmune diseases and oncology through the design of highly selective kinase inhibitors. Its lead candidate, GS-001, is a potent TYK2 inhibitor currently in Phase 1 clinical trials for the treatment of psoriasis and other inflammatory conditions. By leveraging a precision medicine approach, Gerstle Medicine aims to develop therapies with superior safety and efficacy profiles compared to existing treatments. The company is supported by a team of experienced drug discovery professionals and is actively expanding its pipeline of novel therapeutic candidates.